Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And I think there's going to be some, I think, good opportunities over the next couple of years, especially with some of the investments we're making in terms of Shield and really the infrastructure there that is going to, I think, pay dividends on the oncology side as well |
| Biopharma volume increased 15% year-over-year, primarily driven by the uptake of GuardantINFINITY, which also led to an improved biopharma ASP in 2023 of approximately $3,700 compared to $3,610 in 2022 |
| Guardant360 continues to be the main revenue driver, with strong year-over-year volume growth across all cancers in the US, as well as volume contribution from Japan and the UK in the fourth quarter |
| And it's certainly one of the I think potential upside drivers of volume this year |
| But I'm very pleased with the progress the team has made |
| Biopharma test volume was strong in the fourth quarter, totaling approximately 9,500 tests, up 16% from the prior year quarter |
| I'm excited to share that we upgraded Reveal to the smart liquid biopsy platform at the end of the year, enabling even better performance |
| Reveal volumes came in strong with full year growth of over 90% |
| We also received additional commercial coverage for Reveal in CRC following Medicare reimbursement in 2022 and continued to produce compelling data across CRC and breast cancer for Reveal, demonstrating high clinical performance |
| And so, we think we're very pleased with the progress we've made |
| While we continue to believe the performance of Shield meets the bar for FDA approval, we have already demonstrated improved clinical sensitivity with our upgraded platform Shield V2, when compared to Shield V1 with data presented at our Investor Day last year |
| I'm so proud of our team for pushing the boundaries of what's possible as we deliver on our bold mission to give everyone more time free from cancer |
| This story highlights how Reveal can be used effectively in surveillance settings to identify the need for additional treatment and deliver better patient outcomes |
| We had a strong finish to the year with revenue growing 22% to $155 million in the fourth quarter and 25% to $564 million for the full year 2023, coming in slightly above our preannounced range provided in January |
| So we're very pleased in terms of where we are |
| This increase was predominantly driven by strong year-over-year growth in both clinical and biopharma volumes |
| [Multiple Speakers] is very, very strong |
| Clinical testing revenue was $403.9 million, which grew 35% year-over-year, driven by a 39% increase in clinical testing volume |
| Looking forward, our robust companion diagnostic pipeline, coupled with a backlog of deals won, positions us for continued growth in 2024 |
| The strong volume growth was driven by Guardant360, with growth across all cancer types, TissueNext which grew more than 80% and Reveal which grew over 90% |
| We made great strides in improving ASPs for Guardant360 over the last few quarters |
| We're also starting to see the positive impact on Guardant360 ASP from commercial payer coverage wins and believe that this is a tailwind that will continue to play out in the coming year |
| To that end, we continue to make excellent progress integrating with the three largest oncology EMR systems with rapid growth of digital adoption |
| We believe these integrations will serve as a catalyst for increasing ordering depth for accounts throughout the year |
| So, we feel very good, including around the competitive landscape that's there |
| We continue to see strong momentum as we expand our testing offering globally |
| Starting with Therapy Selection, after years of investing in our infrastructure, I'm very pleased that Therapy Selection reached cashflow breakeven at the end of the year, marking a major achievement for Guardant |
| And when we looked at the breakdown there in terms of triple negative, HER2 positive, HER2 negative, and so on, we've seen very a good performance as well there |
| So, that should also lead to good volume growth |
| I would also say that I think we feel very good about the core business in general |
| Statement |
|---|
| It's currently a gross margin negative test for us |
| Accordingly, free cash flow was negative $345 million for the full year of 2023 |
| Development services and other revenue declined 14% to $49.7 million in 2023 |
| Free cash flow for the fourth quarter of 2023 was negative $82.8 million compared to a negative $100.8 million in Q4 2022 |
| For the full year 2023, adjusted EBITDA was a loss of $344.2 million in 2023, which represents a $59.2 million reduction compared to a loss of $403.4 million in 2022 |
| Adjusted EBITDA was a loss of $78.4 million in the fourth quarter of 2023 compared to a $109.8 million loss in the fourth quarter of 2022 |
| Re-screening rate with Cologuard is also low after all these years |
| And it looks kind of common sense that when they're issuing CRC screening, it's lack of adherence, frankly, people are not completing the test |
| And then that always – as companies or customers push through their budgets at the end of the year, and we know that, sequentially, biopharma revenue is always lower in Q1 |
| This reduction was in line with our guidance at the start of 2023 and primarily due to the variable timing, progress and milestones related to projects with third parties, as well as the year-over-year reduction in royalty revenue |
| So even though we'll have an uplift of G360 ASP in Q1, we still expect the overall revenue sequentially to be lower in Q1 versus Q4 of 2023 |
| Total research and development, sales and marketing and G&A operating expenses for the full year 2023 were $818.2 million, a decrease of $19.4 million compared to 2022 |
| While we saw improvements in the gross margin for clinical Guardant360 tests due to the increase in ASP, the overall precision oncology gross margin declined slightly due to changes in the mix of clinical and biopharma tests, the mix of Guardant360, TissueNext and Reveal tests, and the mix of US and international tests |
| So more or less every sort of additional dollar of gross profit is dropping down to the bottom line in Therapy Selection |
| Even in better scenarios, this is a very expensive program with a really long runway |
| Net loss was $187.0 million or $1.58 per share for the fourth quarter of 2023 compared to $139.9 million or $1.36 per share in the fourth quarter of 2022 |
| I think as the as the revenue grows, again, a lot of that's going to start to drop down to the bottom line |
| The slight year-over-year decline is consistent with the change we saw in the fourth quarter where increases in ASP have been more than offset by changes in product mix |
| It's going to be difficult for us to say what the impact is going to be throughout 2024 on screening |
| So to some extent, for Shield, to score well, the USPSTF will have to fundamentally change the methodology that they've used in the past |
Please consider a small donation if you think this website provides you with relevant information